Ibrutinib-specific off-targets LCK, JAK3, and FLT3 were predicted to trigger inflammation processes related to hypertension; ERBB2, BLK, SRC, and CSK were predicted to trigger oxidative stress and endothelial dysfunction; and CSK were predicted to trigger the RAAS overactivation. Here, ERBB2 is linked to endothelial dysfunction.